PR Newswire ScinoPharm Sales Soar 01.24.06,
2:49 AM ET
TAINAN, Taiwan, Jan. 24 /Xinhua-PRNewswire/ -- For the
third consecutive year, ScinoPharm Taiwan, Ltd. has witnessed monumental
growth in its API (active pharmaceutical ingredient) business. The
company's total sales in 2005 reached US$31MM, compared to US$17MM in 2004
and US$7.6MM in 2003.
A number of
biotech companies are collaborating with ScinoPharm on new drug
development. So far, more than 40 NCE (new chemical entity) projects have
been executed, with five of them in the Phase III stage of clinical
trials. Among the NCE projects, one has been commercialized and one
customer listed ScinoPharm as the only supplier in its NDA (new drug
application). A second API for NCE projects is expected to be introduced
in a year.
Meanwhile, ScinoPharm is
also well positioned to capitalize on the generic business opportunities.
To date, ScinoPharm has received 20 DMFs (drug master files) from the US
FDA, and a combined total of 40 DMFs from Canada, Europe, Australia and
New Zealand. More than 30 generic APIs have been developed with six of
them being commercialized so far.
In
addition, ScinoPharm offers a wide array of services including R&D,
process development and manufacturing in compliance to cGMP to brand
pharma. To that end, ScinoPharm has successfully established business
partnership with seven of the top 10 brand companies.
Additional information is available from the company's
website at www.scinopharm.com .
CONTACT: Maggie Lin Tel:
+866-6-505-2888 Ext. 2833 Fax: +886-6-505-2889 Email:
magie.lin@scinopharm.com.tw WEB: www.scinopharm.com SOURCE ScinoPharm
Taiwan, Ltd. -0- 01/24/2006 /CONTACT: Maggie Lin of ScinoPharm Taiwan,
+866-6-505-2888 Ext. 2833, or fax, +886-6-505-2889, or
magie.lin@scinopharm.com.tw/ /Web site: http://www.scinopharm.com / CO:
ScinoPharm Taiwan, Ltd. ST: Taiwan IN: HEA BIO MTC SU: ERN JC -- HKTU004
-- 2443 01/24/2006 02:47 EST http://www.prnewswire.com
Stock quotes are delayed at least 15 minutes for Nasdaq,
at least 20 minutes for NYSE/AMEX. U.S. indexes are delayed at least 15 minutes
with the exception of Nasdaq, Dow Jones Industrial Average and S&P 500 which
are 2 minutes delayed.
Reprints/Permissions
Subscriber Services
